Trials / Completed
CompletedNCT02959970
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 9 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dapsone gel | Dapsone (ACZONE) 7.5% gel topically once daily. |
Timeline
- Start date
- 2016-10-31
- Primary completion
- 2018-03-09
- Completion
- 2018-03-09
- First posted
- 2016-11-09
- Last updated
- 2020-03-03
- Results posted
- 2020-02-13
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02959970. Inclusion in this directory is not an endorsement.